Ahead of the Transcatheter Cardiovascular Therapeutics (TCT) 2018 conference, Kirkland, Wash.-based Cardiac Dimensions Inc. reported the randomization of the first patient in the CARILLON pivotal trial for the treatment of functional mitral valve regurgitation (FMR) associated with heart failure. The multicenter, double-blinded, randomized controlled trial is expected to randomize 450 patients at up to 75 centers in North America and Europe. Read More
